Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE)

All products: general benefit

Other products in the same Health Canada class (A06A, A06AA) — coverage varies; not interchangeable

  • Mineral oil (Fleet Enema Mineral Oil): general benefit
  • Bisacodyl (Dulcolax): general benefit
  • Citrus fibre + grain (Novo-Fibre): general benefit, Not a benefit
  • Lactulose (PMS-Lactulose): general benefit
  • Citric acid + oxide + picosulfate (Pico-Salax): general benefit

Soflax · DIN 01994344 · 100mg · capsule

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Soflax · DIN 01994344 Manufacturer: Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 1993-12-31 · brand SOFLAX CAPSULES 100MG · ATC A06AA02 DOCUSATE SODIUM · form Capsule · route Oral · ingredients DOCUSATE SODIUM 100 MG · company Pharmascience inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Soflax: Formulary list price $0.0328/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0328 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14487 · Verify on the e-Formulary ↗ (DIN 01994344)

Source record
DIN 01994344: Soflax Raw flags: sec3=Y, selfMed=Y Item: 561200008; group id 649; item number 1629; lccId None; manufacturer id PMS Source form: Cap; strength: 100mg Recorded listing: General benefit; self-medication (OTC-type) product Source prices (unrounded): $0.0328; ministry $0.0328 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01994344 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14487
Interchangeable products
Colace · DIN 02106256 · $0.0328 Docusate Sodium · DIN 00716731 · $0.0328 Jamp-Docusate Sodium · DIN 02245946 · $0.0328
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (56:12 Cathartics) and how they are covered

Matched class: 56:12 Cathartics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BISACODYL, LACTULOSE, MAGNESIUM OXIDE & CITRIC ACID & SODIUM PICOSULFATE, MINERAL OIL, PSYLLIUM MUCILLOID, SENNOSIDES A & B, SODIUM BIPHOSPHATE & SODIUM PHOSPHATE Some products covered without a code (check the product listing): GRAIN & CITRUS FIBRE 56:12 Cathartics

MINERAL OIL

· 1 products · General benefit · strengths: 100% · Enema

BISACODYL

· 5 products · General benefit · strengths: 5mg, 10mg · Ent Tab, Sup

GRAIN & CITRUS FIBRE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: · Tab

LACTULOSE

· 1 products · General benefit · strengths: 667mg/mL · O/L

MAGNESIUM OXIDE & CITRIC ACID & SODIUM PICOSULFATE

· 2 products · General benefit · strengths: 3.5g & 12g & 10mg · Pd for Sol-12g Sachet

PSYLLIUM MUCILLOID

· 1 products · General benefit · strengths: · Oral Pd

SENNOSIDES A & B

· 2 products · General benefit · strengths: 8.6mg · Tab

SODIUM BIPHOSPHATE & SODIUM PHOSPHATE

· 2 products · General benefit · strengths: 160mg & 60mg/mL · Ped Rect Sol, Rect Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:12
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:16 Digestants, 56:22 Antiemetics and Antinauseants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no link